



PATENT

UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: STEVENS, Fred J. et. al.

Title: "FIBRIL-BLOCKING PEPTIDE, A METHOD FOR PREVENTING FIBRIL FORMATION"

Serial No.: 09/712,819

Filing Date: November 13, 2000

Examiner: Dr. Phuong N. Huynh

Art Unit: 1644

Attny Docket: 0003/00537

CERTIFICATE OF MAILING: I hereby certify that this correspondence is being deposited per 37 C.F.R. 1.8 with the United States Postal service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C., 20231 on July 17, 2003 (Date of Deposit).

Jillian Szafranski
Name of Representative

Jillian Szafranski
Signature

July 17, 2003
Date of Signature

Commissioner for Patents
Alexandria, VA 22313

20 N. Wacker Drive
Chicago, IL 60606
312-621-1330

RESPONSE TO NOTICE TO COMPLY WITH THE SEQUENCE RULES

Sir:

In response to the July 2, 2003 Notice to Comply With The Sequence Rules in the above-identified matter, Applicant submits the enclosed replacement compact disc and hard copy of the sequence.

REMARKS

The July 2, 2003 Notice to Comply indicates that the computer readable form submitted on April 8, 2003 contains a total of 11 sequences while the paper copy has a total of 13 sequences. As such, the sequences contained therein are not in compliance with the Sequence Rules, 37 C.F.R. Sections 1.821-1.825. The instant sequence is

In re STEVENS et al. (S.N. 09/712,819)
Response to July 2, 2003 Official Action
Page -2-

being submitted herewith in hard copy form and compact disk form such that the each form contains a total of 13 sequences.

The applicant submits that the content of the computer readable copy is the same as the paper copy. No new matter is submitted herein.

Applicant requests entry of the sequence listing into the instant specification.

Respectfully submitted,

CHERSKOV & FLAYNIK

By 

Michael J. Cherskov (Reg. No. 33,664)

O P E
JUL 21 2003

Application No.: 09/712,819



**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- 7. Other: The computer readable file submitted on 4/8/03 has a total of 11 sequences while the paper copy has a total of 13 sequences. Further, SEQ ID NO is required for peptide such as the ones disclosed on pages 3, 5-6, 8-10 and 15 of the specification.

Applicant Must Provide:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support (SIRA)

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE